I am/have/had
I am looking for
Advanced Filters
Found 1 clinical trials
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
This is a Phase 1, multicenter, open-label, multiple-dose, dose-escalation and dose-expansion study to evaluate the safety, tolerability, PK, and pharmacodynamics of TTX-080 monotherapy in subjects with advanced or metastatic solid tumors known to express HLA-G. This first-in-human (FIH) study has been designed to evaluate the safety, tolerability, and preliminary antitumor …
solid tumour
metastasis
measurable disease
cancer
hla-g
- 0 views
- 05 Aug, 2020